Cel-Sci Corporation
CVM
|
$1.56
4.0%
0.0%
230K
|
Health Technology
(0.0% 1d) (-17.5% 1m) (-38.1% 1y) (0.0% 2d) (0.0% 3d) (-1.9% 7d) (32.45% volume)
Earnings Calendar:
Market Cap: $ 84,207,600
http://www.cel-sci.com
Sec Filling | Patents | 2020 employees
(United States) CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.
vaccine cancer immunotherapy infectious disease rheumatoid arthritis influenza treatment
add to watch list Paper trade email alert is off
Press-releases
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
Published: 2024-03-19 (Crawled : 13:30) - biospace.com/
CVM | $1.56 4.0% 0.0% 230K
|
Health Technology
|
| O: 0.0%
H: 1.46%
C: -0.98%
vaccine treat immunology
CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results
Published: 2024-02-15 (Crawled : 15:00) - biospace.com/
CVM | $1.56 4.0% 0.0% 230K
|
Health Technology
|
| O: 0.0%
H: 1.68%
C: -0.84%
first corporation financial results
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
Published: 2024-02-13 (Crawled : 19:00) - biospace.com/
CVM | $1.56 4.0% 0.0% 230K
|
Health Technology
|
| O: 1.27%
H: 0.0%
C: -4.18%
million offering
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
Published: 2024-02-09 (Crawled : 14:30) - biospace.com/
CVM | $1.56 4.0% 0.0% 230K
|
Health Technology
|
| O: -17.54%
H: 9.97%
C: 4.68%
million offering
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
Published: 2024-01-31 (Crawled : 21:00) - biospace.com/
CVM | $1.56 4.0% 0.0% 230K
|
Health Technology
|
| O: 1.75%
H: 6.21%
C: -1.03%
multikine authorization grants
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
Published: 2023-12-22 (Crawled : 16:00) - biospace.com/
CVM | $1.56 4.0% 0.0% 230K
|
Health Technology
|
| O: 3.75%
H: 1.08%
C: -0.72%
financial results
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
Published: 2023-11-16 (Crawled : 14:30) - biospace.com/
CVM | $1.56 4.0% 0.0% 230K
|
Health Technology
|
| O: -21.88%
H: 5.22%
C: -0.89%
offering
CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals
Published: 2023-10-24 (Crawled : 14:00) - biospace.com/
CVM | $1.56 4.0% 0.0% 230K
|
Health Technology
|
| O: -3.97%
H: 7.59%
C: 5.52%
CEL-SCI Files Request With the UK’s MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer
Published: 2023-10-05 (Crawled : 13:30) - biospace.com/
CVM | $1.56 4.0% 0.0% 230K
|
Health Technology
|
| O: 0.86%
H: 4.26%
C: -6.84%
multikine approval cancer treatment
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
Published: 2023-08-11 (Crawled : 21:00) - biospace.com/
CVM | $1.56 4.0% 0.0% 230K
|
Health Technology
|
| O: -0.7%
H: 0.71%
C: -12.06%
corporation financial results
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10